Nureca Limited has informed the Exchange regarding Outcome of Board Meeting held on May 05, 2025.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 0.6 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nureca Limited's board approved its audited financial results (standalone and consolidated) for Q4 and FY ending March 31, 2025, with an unmodified opinion from statutory auditors B S R & Co. LLP. Notably, the standalone results for FY25 reflect a net loss. The board appointed M/s Singhi & Co as the new statutory auditor for a 5-year term, replacing B S R & Co. LLP whose term ends at the 9th AGM. It also in-principle approved the merger of its wholly-owned subsidiary Nureca Technologies Private Limited (FY25 standalone revenue ₹228.14 million, net worth ₹53.94 million) into Nureca Limited (FY25 standalone revenue ₹1,146.40 million, net worth ₹1,917.38 million). No new shares will be issued under the scheme, so shareholding pattern remains unchanged. Several directors were re-appointed for fresh 5-year terms, and the 9th AGM is scheduled for June 16, 2025 via video conferencing.
Shareholders should note that FY25 standalone results show a net loss, which is a key negative signal. The routine auditor change from B S R & Co. to Singhi & Co. is unlikely to be disruptive, while the subsidiary merger is aimed at simplifying the group structure and reducing overheads with no dilution.